ReviewPediatric investigation2023
Multilevel omics for the discovery of biomarkers in pediatric sepsis.
Review in Pediatric investigation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 17 citations in OpenAlex.
- Early recognition and bundle-based management of pediatric sepsis in the emergency department: a narrative review.Translational pediatrics · 2026Review
- Multi-omics insights into immunometabolic dysregulation in neonatal sepsis for precision medicine.Molecular biology reports · 2026Review
- Multiomics characterization of acute child illness and mortality in Africa and South Asia.Nature communications · 2026Article
- Proteomic biomarkers for early diagnosis and prognosis in pediatric sepsis.World journal of clinical pediatrics · 2026Article
- Plasma Proteomic Signatures of Pediatric Sepsis Reveal Persistent Inflammation and Phase-Specific Biomarkers.FASEB bioAdvances · 2026Article
- Serum HMGB1 as a biomarker and predictive model for pediatric septic shock: a cohort study.Translational pediatrics · 2026Article
- Multi-omic and computational approaches for biomarker discovery and clinical translation in pediatric sepsis.Frontiers in pharmacology · 2026Review
- Research Progress on Sepsis Diagnosis and Monitoring Based on Omics Technologies: A Review.Diagnostics (Basel, Switzerland) · 2025Review
- The gut dysbiosis and plasma lipid metabolisms signatures in children with active tuberculosis.BMC microbiology · 2025Article
- Unraveling the promise and challenges of biomarkers in pediatric sepsis: a commentary on risk estimation of organ dysfunction and immune dysregulation.Pediatric research · 2025Article
- A diagnostic model for sepsis using an integrated machine learning framework approach and its therapeutic drug discovery.BMC infectious diseases · 2025Article
- New Criteria for Pediatric Sepsis: A Phoenix Rising.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2024Article
- Struggling to Understand the NEC Spectrum-Could the Integration of Metabolomics, Clinical-Laboratory Data, and Other Emerging Technologies Help Diagnosis?Metabolites · 2024Review
- Characteristics and Risk Factors for Pediatric Sepsis.Current medical science · 2024Article
- Article
- The predictive value of peripheral blood cell mitochondrial gene expression in identifying the prognosis in pediatric sepsis at preschool age.Frontiers in cellular and infection microbiology · 2024Article
- Multilevel omics for the discovery of biomarkers in pediatric sepsis.Pediatric investigation · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe sepsis causes organ dysfunction and continues to be the leading reason for pediatric death worldwide. Early recognition of sepsis could substantially promote precision treatment and reduce the risk of pediatric death. The host cellular response to infection during sepsis between adults and pediatrics could be significantly different. A growing body of studies focused on finding markers in pediatric sepsis in recent years using multi-omics approaches. This narrative review summarized the progress in studying pediatric sepsis biomarkers from genome, transcript, protein, and metabolite levels according to the omics technique that has been applied for biomarker screening. It is most likely not a single biomarker could work for precision diagnosis of sepsis, but a panel of markers and probably a combination of markers detected at multi-levels. Importantly, we emphasize the importance of group distinction of infectious agents in sepsis patients for biomarker identification, because the host response to infection of bacteria, virus, or fungus could be substantially different and thus the results of biomarker screening. Further studies on the investigation of sepsis biomarkers that were caused by a specific group of infectious agents should be encouraged in the future, which will better improve the clinical execution of personalized medicine for pediatric sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.